Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3457–3466. doi: 10.1158/1055-9965.EPI-08-0517

Table 3.

Age-adjusted ORs and 95% CIs for CYP19A1 genotypes and risk of breast cancer with proliferative fibrocystic conditions, by menopausal status and BMI

By menopausal status By BMI


Controls Breast cancer cases
with proliferative fibrocystic conditions
Controls Breast cancer cases
with proliferative fibrocystic conditions


Pre Post Premenopausal Postmenopausal <23 23+ <23 kg/m2 23+ kg/m2


n n n OR 95% CI n OR 95% CI n n n OR 95% CI n OR 95% CI
Block 1
rs1870049
TT 333 215 41 1.00 (ref) 26 1.00 (ref) 242 306 25 1.00 (ref) 41 1.00 (ref)
CT 166 126 21 1.04 (0.60–1.82) 20 1.30 (0.70–2.42) 127 165 13 0.98 (0.48–1.99) 28 1.26 (0.75–2.12)
CC 29 9 6 1.64 (0.64–4.19) 2 1.90 (0.39–9.34) 16 22 4 2.42 (0.75–7.82) 4 1.41 (0.46–4.33)
rs1870049
TT 256 154 30 1.00 (ref) 14 1.00 (ref) 186 224 21 1.00 (ref) 22 1.00 (ref)
CT 210 161 25 1.03 (0.58–1.80) 23 1.54 (0.76–3.10) 161 210 11 0.59 (0.28–1.27) 37 1.78 (1.01–3.11)
CC 59 31 11 1.53 (0.72–3.25) 10 3.66 (1.48–9.02) 35 55 9 2.29 (0.97–5.42) 12 2.23 (1.04–4.78)
Block 2
rs28566535
AA 245 159 28 1.00 (ref) 17 1.00 (ref) 187 217 20 1.00 (ref) 25 1.00 (ref)
AC 214 156 29 1.16 (0.67–2.02) 16 0.93 (0.46–1.92) 160 210 14 0.81 (0.40–1.66) 30 1.23 (0.70–2.17)
CC 63 31 10 1.33 (0.61–2.89) 13 4.03 (1.77–9.18) 33 61 8 2.27 (0.92–5.59) 15 2.15 (1.07–4.33)
rs936306
CC 250 155 29 1.00 (ref) 20 1.00 (ref) 185 220 20 1.00 (ref) 29 1.00 (ref)
CT 212 156 28 1.11 (0.64–1.93) 14 0.68 (0.33–1.39) 161 207 15 0.86 (0.42–1.73) 26 0.94 (0.54–1.66)
TT 65 37 10 1.27 (0.59–2.75) 14 3.00 (1.38–6.51) 38 64 7 1.71 (0.67–4.33) 17 2.01 (1.04–3.89)
Block 3
rs11636639
GG 145 99 18 1.00 (ref) 13 1.00 (ref) 102 142 13 1.00 (ref) 17 1.00 (ref)
GT 243 167 33 1.15 (0.62–2.14) 26 1.18 (0.58–2.40) 184 226 20 0.86 (0.41–1.82) 39 1.42 (0.77–2.61)
TT 130 68 16 1.00 (0.49–2.04) 9 1.08 (0.43–2.69) 91 107 9 0.79 (0.32–1.95) 16 1.27 (0.61–2.63)
Block 4
rs767199
AA 116 69 12 1.00 (ref) 5 1.00 (ref) 80 105 8 1.00 (ref) 9 1.00 (ref)
AG 254 184 36 1.44 (0.72–2.89) 23 1.69 (0.62–4.63) 198 240 24 1.21 (0.52–2.81) 35 1.68 (0.78–3.62)
GG 158 97 19 1.16 (0.54–2.49) 19 2.65 (0.94–7.46) 107 148 10 0.93 (0.35–2.47) 27 2.12 (0.96–4.69)
rs4775936
TT 110 64 12 1.00 (ref) 4 1.00 (ref) 73 101 6 1.00 (ref) 10 1.00 (ref)
CT 262 197 31 1.10 (0.55–2.23) 24 1.91 (0.64–5.73) 205 254 23 1.37 (0.54–3.51) 32 1.23 (0.58–2.60)
CC 155 88 24 1.42 (0.68–2.97) 20 3.57 (1.16–10.97) 106 137 13 1.50 (0.54–4.13) 30 2.17 (1.01–4.65)
rs11575899
INS/INS 272 181 33 1.00 (ref) 24 1.00 (ref) 194 259 19 1.00 (ref) 38 1.00 (ref)
INS/DEL 211 147 25 0.98 (0.57–1.71) 20 1.05 (0.56–1.99) 158 200 17 1.10 (0.55–2.18) 27 0.93 (0.55–1.57)
DEL/DEL 45 20 9 1.69 (0.76–3.78) 3 1.13 (0.31–4.10) 31 34 5 1.65 (0.57–4.74) 7 1.43 (0.59–3.46)
rs10046
TT 168 109 21 1.00 (ref) 9 1.00 (ref) 120 157 10 1.00 (ref) 20 1.00 (ref)
CT 253 183 38 1.25 (0.70–2.21) 29 1.89 (0.86–4.16) 190 246 28 1.77 (0.83–3.77) 39 1.23 (0.69–2.18)
CC 107 56 8 0.60 (0.25–1.40) 9 1.96 (0.74–5.22) 73 90 3 0.49 (0.13–1.85) 13 1.14 (0.54–2.40)
rs4646
GG 264 177 35 1.00 (ref) 21 1.00 (ref) 183 258 20 1.00 (ref) 36 1.00 (ref)
GT 210 148 27 0.97 (0.57–1.66) 23 1.33 (0.71–2.51) 164 194 20 1.12 (0.58–2.15) 29 1.07 (0.64–1.81)
TT 54 23 5 0.71 (0.27–1.91) 3 1.09 (0.30–3.94) 36 41 1 0.25 (0.03–1.95) 7 1.25 (0.52–2.99)
HHS Vulnerability Disclosure